CAMBRIDGE, Mass., March 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences. Infinity’s Hedgehog pathway inhibitor, IPI-926, is a potent, orally-delivered small molecule drug candidate that has demonstrated significant anti-tumor activity in multiple preclinical cancer models and in settings where the malignant activation of the pathway is implicated in difficult-to-treat cancers. IPI-926 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. Data from this trial are expected to be presented in 2010, and Infinity anticipates initiating Phase 2 development with IPI-926 later this year.
